When to repeat thyroid ultrasound for a TI-RADS (Thyroid Imaging Reporting and Data System) category 4 nodule of 1.2 cm size?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2025 • View editorial policy

From the Guidelines

For a TI-RADS category 4 thyroid nodule measuring 1.2 cm, follow-up ultrasound is recommended in 6-12 months, with subsequent annual ultrasound surveillance for at least 3-5 years if the nodule remains stable. This recommendation is based on the moderate suspicion for malignancy (5-20%) associated with TI-RADS 4 nodules, as suggested by the American College of Radiology Appropriateness Criteria 1. Fine needle aspiration (FNA) biopsy should also be considered for this nodule since it exceeds 1 cm in size, which is the typical threshold for biopsy of TI-RADS 4 nodules, according to the ESMO clinical practice guidelines for diagnosis, treatment, and follow-up of thyroid cancer 2, 3. Some key points to consider during follow-up include:

  • Monitoring for concerning changes such as increased size (>20% increase in two dimensions or >50% increase in volume)
  • Development of suspicious features like irregular margins, microcalcifications, or abnormal vascularity
  • Earlier intervention or repeat biopsy may be warranted if such changes occur, regardless of the original follow-up timeline It is essential to discuss the nodule's nature and the follow-up plan with a physician, especially if an FNA has not been performed yet, as it provides more definitive information about the nodule's nature 2.

From the Research

Thyroid Ultrasound Follow-up for TI-RADS Category 4 Nodules

  • The American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) provides a framework for assessing the malignancy risk of thyroid nodules 4.
  • For TI-RADS category 4 nodules, the current recommendation is to perform fine-needle aspiration (FNA) for nodules ≥1.5 cm in size, but there is no clear guidance on the follow-up interval for smaller nodules 4.
  • A study published in 2022 found that a TI-RADS score of ≥4 had an 84% positive predictive value (PPV) for malignancy, suggesting that category 4 nodules may require closer follow-up 5.
  • Another study published in 2019 found that the ACR TI-RADS system had high diagnostic value in differentiating malignant from benign thyroid nodules in a pediatric population, with a high likelihood of malignancy associated with TI-RADS category 4 or 5 nodules 6.
  • However, there is limited evidence specifically addressing the follow-up interval for TI-RADS category 4 nodules of 1.2 cm size, and the optimal follow-up strategy may depend on individual patient factors and clinical judgment 7, 8.

Factors Influencing Follow-up Recommendations

  • Nodule size: Larger nodules are generally considered to be at higher risk of malignancy and may require more frequent follow-up 4, 5.
  • Patient age and medical history: Pediatric patients and those with a history of radiation exposure may be at higher risk of thyroid cancer and may require more frequent follow-up 6.
  • Ultrasound features: Nodules with suspicious ultrasound features, such as irregular margins or microcalcifications, may require more frequent follow-up 8.

Current Recommendations

  • The ACR TI-RADS system recommends FNA for TI-RADS category 4 nodules ≥1.5 cm in size, but does not provide specific guidance on the follow-up interval for smaller nodules 4.
  • The American Thyroid Association (ATA) recommends annual ultrasound follow-up for nodules ≥1 cm in size with suspicious features, but does not provide specific guidance on the follow-up interval for TI-RADS category 4 nodules 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.